ArticleJournal of pharmacy & bioallied sciences
A Comparative Evaluation of Cut 380A Intrauterine Device Versus Depot Medroxyprogesterone Acetate For Long-Acting Reversible Contraception.
Article in Journal of pharmacy & bioallied sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: India's family-planning program increasingly emphasizes long-acting reversible contraceptives (LARCs) to curb unintended pregnancy. Copper T 380A (CuT 380A) intrauterine device (IUCD) and injectable depot medroxyprogesterone acetate (DMPA) are the two program-supported LARCs, yet granular comparative Indian data remain scarce. Methods: We undertook a prospective longitudinal study (November 2016-March 2018) at Safdarjung Hospital, New Delhi. Women choosing CuT 380A or DMPA were enrolled consecutively and stratified by timing of initiation-postpartum, postabortion, or interval. Baseline demographics, adverse events, continuation, discontinuation, expulsion, and pregnancy were recorded at 1, 3, 6, 9, and 12 months. Comparative statistics employed χ Results: A total of 162 women were analysed (81 per group), with a mean age of approximately 28 years. Baseline characteristics were comparable between groups. At 12 months, continuation was significantly higher with CuT 380A (74.0%) than DMPA (39.5%) ( Conclusion: Both LARCs were safe and highly effective; however, CuT 380A demonstrated superior 12-month continuation and satisfaction, whereas DMPA exhibited a higher drop-out largely driven by bleeding changes and desire for pregnancy. High-quality counselling on anticipated bleeding patterns could further optimize DMPA continuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.